TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04267848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Undergo observation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02954406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine intravenous infusion
Study: NCT01944761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Designed to improve cardio-respiratory fitness, the exercise program will be conducted for 12 weeks at a frequency of 3-4 sessions per week. Each exercise session will be conducted after school for a total duration of 90 minutes (group sessions) or 30 minutes (home-based sessions). Group session activities will include i) warm-up (i.e. walk/jog, games) \[10 mins\], ii) aerobic training/fitness games \[30 mins\], iii) organized sports \[30 mins\], iv) cool down (i.e. stretching, low intensity games) \[10 mins\] and v) snack and reward (15 mins).~Participants in the Group setting had three 90-minute group sessions per week. Participants in the Combined setting had two 90-minute group sessions and two 30-minute individual home-based sessions per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Designed to improve cardio-respiratory fitness, the exercise program will be conducted for 12 weeks at a frequency of 3-4 sessions per week. Each exercise session will be conducted after school for a total duration of 90 minutes (group sessions) or 30 minutes (home-based sessions). Group session activities will include i) warm-up (i.e. walk/jog, games) \[10 mins\], ii) aerobic training/fitness games \[30 mins\], iii) organized sports \[30 mins\], iv) cool down (i.e. stretching, low intensity games) \[10 mins\] and v) snack and reward (15 mins).~Participants in the Group setting had three 90-minute group sessions per week. Participants in the Combined setting had two 90-minute group sessions and two 30-minute individual home-based sessions per week.
Study: NCT02954406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib capsule
Study: NCT00778258

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baked Milk
Description: At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baked Milk
Description: At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baked Milk
Description: At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baked Milk
Description: At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baked Milk
Description: At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-baked Milk
Description: Those subjects tolerant to rice pudding will undergo oral food challenge with non-baked milk.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-baked Milk
Description: Those subjects tolerant to rice pudding will undergo oral food challenge with non-baked milk.
Study: NCT01905228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL0137
Description: All doses are administered intravenously on Days 1, 8 and 15 of every 28 day cycle.~Number of Cycles: 2 or until progression or unacceptable toxicity develops
Study: NCT00362271

Intervention type: DRUG
Group type: OTHER
Intervention: Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.
Description: Tablets, Oral, Venlafaxine: 75 mg; Aripiprazole: 10, 15, 20 mg once daily, 14 days.
Study: NCT04870307

Intervention type: OTHER
Group type: OTHER
Intervention: Dissemination and Implementation Research
Description: Dissemination and Implementation research involves assisting primary care practices to address SARS-CoV-2 testing using evidence-based practices as well as increased testing in mobile-based community settings. The D\&I model also involves Practice Assessment, Academic Detailing, Practice Facilitation, Health Information Technology Support, Performance Feedback and Benchmarking, and a Virtual Learning Community.
Study: NCT04432506

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Given SC
Study: NCT03825315

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
Study: NCT01842074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
Study: NCT02050529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labetalol
Description: Group A( Labetalol) will be receive intravenous labetalol bolus doses as specified in protocol summary.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydralazine
Description: Group B(Hydralazine) will serve as control and will receive active comparator Hydralazine intravenous bolus doses as specified in summary.
Study: NCT02292277

Intervention type: DRUG
Intervention: Ticagrelor
Description: Oral loading dose of 180 mg ticagrelor.

Intervention type: DRUG
Intervention: Ticagrelor
Description: Oral loading dose of 180 mg ticagrelor.
Study: NCT04432506

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: Given IV
Study: NCT00583778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ipratropium
Description: 0.5 mg of ipratropium added to 1.25 mg levalbuterol given every 20 minutes for 3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipratropium
Description: 0.5 mg of ipratropium added to 1.25 mg levalbuterol given every 20 minutes for 3 doses
Study: NCT02167893

Intervention type: DRUG
Intervention: Leuprorelin acetate
Description: Leuprorelin acetate SR 11.25 mg injection kit
Study: NCT00573469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D9421-C, 9mg
Description: D9421-C 9 mg was given once daily for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D9421-C, 15mg
Description: D9421-C 15 mg was given once daily for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: D9421-C matching placebo was given once daily for 8 weeks.
Study: NCT03111901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 solution
Study: NCT04432506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study: NCT03924895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
Description: Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
Description: Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Enfortumab vedotin 1.25 mg/kg by intravenous (IV) infusion, given on Days 1 and 8 of each 21-day cycle.
Study: NCT04227769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra Prefilled Syringe
Description: Subcutaneous injection of 100 mg/ 0.67 ml of Kineret or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra Prefilled Syringe
Description: Subcutaneous injection of 100 mg/ 0.67 ml of Kineret or placebo
Study: NCT00609869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide was administered orally with escalating doses on 28-days cycles. The first cycle was administered with a starting dose of 2.5 mg daily on days 1-7, 5mg on days 8-14 and 10 mg on days 15-21, followed by seven days off. On cycle 2 and beyond lenalidomide was administered at 20 mg daily on days 1-21.
Study: NCT01677598

Intervention type: DRUG
Intervention: No intervention
Description: No intervention will be administered during study. This will be an observational study in patients using ustekinumab as label-recommended or other/missed dose interval in Asia-Pacific countries
Study: NCT00609869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab was administered at 375 mg/m\^2 intravenously on a weekly basis for the first cycle starting on day 15. Subsequent rituximab doses were administered on day one of cycle 2 and beyond, every 4 weeks. Doses were repeated on 28-day cycles until disease progression or unacceptable toxicity, but were planned for 12 cycles.
Study: NCT03926624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFP-10917
Description: DFP-10917 Powder for Injection. Active ingredient: 4-amino-1-(2-cyano-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone monohydrochloride
Study: NCT02314897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LV pacing
Description: Left ventricular pacing lead implanted via the coronary sinus.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RV pacing
Description: Conventional right ventricular pacing.
Study: NCT01613404

Intervention type: OTHER
Intervention: No intervention
Description: Patients will be treated with approved erythropoiesis stimulating agent (Eprex or Aranesp) will be administered according to actual clinical practice according to guidance in the current approved product monographs. All patients will receive treatments that are prescribed by their physician according to actual clinical practice.

Intervention type: OTHER
Intervention: No intervention
Description: Patients will be treated with approved erythropoiesis stimulating agent (Eprex or Aranesp) will be administered according to actual clinical practice according to guidance in the current approved product monographs. All patients will receive treatments that are prescribed by their physician according to actual clinical practice.
Study: NCT04412720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic and Breathing Exercises
Description: Aerobic exercises will be performed on a treadmill, twice a week, totaling 20 sessions of 60 minutes each. The initial intensity will be 50% to 60% of maximum heart rate and the progression will take place according to the level of effort (Borg) in the last two sessions. In addition, following the aerobic training, Buteyko Breathing Technique also will be performed during 20 minutes each exercise, in the same treatment session. During the first two weeks, the patient will learn the technique supervised by a physical therapist. In addition, the patients will receive a breathing exercise booklet for in-home training. Before and after each session, patients will be evaluated in relation to blood pressure, heart rate, oxygen saturation and asthma symptoms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic and Stretching Exercises
Description: Aerobic exercises will be performed on a treadmill, twice a week, totaling 20 sessions of 60 minutes each. The initial intensity will be 50% to 60% of maximum heart rate and the progression will take place according to the level of effort (Borg) in the last two sessions. In addition, following the aerobic training, stretching exercises will be performing for major muscle groups, during 30 seconds each one. The patients will receive a stretching exercise booklet for in-home training.
Study: NCT02108353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 2mg
Description: once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
Study: NCT01366521

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Monoclonal antibody
Study: NCT03924973

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ESDM followed by treatment as usual
Description: The intervention was ESDM, delivered by professionals, one therapist per child, 12 hours per week during 2 years.~Then, they will receive the treatment as usual during 3 years in this current follow-up study.~Precise description of the 2 years ESDM treatment can be found in the published protocol of IDEA.~What is called treatment as usual is what the community can usually offer. That is what the control group in IDEA received.~In IDEA-2, both control and interventional group of IDEA will receive treatment as usual during 3 years.~Treatment as usual comprises of different types of interventions, such as speech pathology therapy, occupational therapy and other types of therapy more or less specific to ASD in the community.~All the interventions received by the children will be monitored in IDEA-2. All different treatment approaches will be quantified (type, frequency, intensity and duration).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESDM followed by treatment as usual
Description: The intervention was ESDM, delivered by professionals, one therapist per child, 12 hours per week during 2 years.~Then, they will receive the treatment as usual during 3 years in this current follow-up study.~Precise description of the 2 years ESDM treatment can be found in the published protocol of IDEA.~What is called treatment as usual is what the community can usually offer. That is what the control group in IDEA received.~In IDEA-2, both control and interventional group of IDEA will receive treatment as usual during 3 years.~Treatment as usual comprises of different types of interventions, such as speech pathology therapy, occupational therapy and other types of therapy more or less specific to ASD in the community.~All the interventions received by the children will be monitored in IDEA-2. All different treatment approaches will be quantified (type, frequency, intensity and duration).
Study: NCT00543140

Intervention type: DEVICE
Group type: OTHER
Intervention: REALIZE™ Swedish Adjustable Gastric Band
Description: Laparoscopic placement of the Swedish Adjustable Gastric Band
Study: NCT04432194

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional supplementation and Pulmonary Rehabilitation
Description: Nutritional supplementation (HMB 4g) or Nutritional supplementation (citrulline 3g) with Pulmonary Rehabilitation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation and Pulmonary Rehabilitation
Description: Nutritional supplementation (HMB 4g) or Nutritional supplementation (citrulline 3g) with Pulmonary Rehabilitation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation and Pulmonary Rehabilitation
Description: Nutritional supplementation (HMB 4g) or Nutritional supplementation (citrulline 3g) with Pulmonary Rehabilitation
Study: NCT03125343

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopy
Description: Continuous follow-up. All patients with complete response will be followed for ten years. Details from the follow-up schedule will be registered in clinical record forms including information on the endoscopic findings, MRI findings and digital examination.~They will be followed ever third month for the first two years as follows:~* PET-CT is optional, but can be performed at inclusion~* Pelvic MRI including diffusion weighted imaging according to appendix C.~* Clinical examination~* Endoscopy (flexible sigmoidoskopy) with photodocumentation~* CEA~After two years the patients will be followed every six month with:~* Pelvic MRI including diffusion weighted imaging according to appendix as at baseline~* Clinical examination~* Endoscopy with photodocumentation~* CEA
Study: NCT03926624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: cytosine arabinoside (ara-C)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine
Study: NCT03787173

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optimized
Description: Inspiratory trigger and Expiratory trigger settings optimized by investigator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated
Description: Inspiratory trigger and Expiratory trigger settings automatized
Study: NCT01730326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1000 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen
Description: 50 mg